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families with blepharophimosis-ptosis-epicanthus
inversus syndrome
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Abstract
Background: Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) is a rare autosomal dominant disease.
Mutations in the forkhead box L2 (FOXL2) gene cause two types of BPES distinguished by the presence (type I) and
absence (type II) of premature ovarian failure (POF). The purpose of this study was to identify possible mutations in
FOXL2 in two Chinese families with BPES.
Methods: Two large autosomal dominant Chinese BPES families were enrolled in this study. Genomic DNA was
obtained from the leukocytes in peripheral venous blood. Four overlapping sets of primers were used to amplify the
entire coding region and nearby intron sequences of the FOXL2 gene for mutations detection using polymerase chain
reaction (PCR) and sequencing analyses. The sequencing results were analyzed using DNAstar software.
Results: All patients of the two families demonstrated typical features of BPES type II, including small palpebral fissures,
ptosis, telecanthus, and epicanthus inversus without female infertility (POF). A novel FOXL2 heterozygous indel
mutation c.675_690delinsT, including a 16-bp deletion and a 1-bp(T) insertion (p.Ala226_Ala230del), which would result
in deletion of 5 alanine residues of a poly-alanine (poly-Ala) tract in the protein, was identified in all affected members
of family A. A novel heterozygous missense mutation (c.223C > T, p.Leu75Phe) was identified in family B.
Conclusions: Two novel FOXL2 mutations were identified in Chinese families with BPES. Our results expand the
spectrum of FOXL2 mutations and provide additional structure-function insights into the FOXL2 protein.
Background
Blepharophimosis-ptosis-epicanthus inversus syndrome
(BPES; OMIM# 110100) is an autosomal dominant de-
velopmental disorder characterized by a malformation of
the eyelids. It has a prevalence of approximately 1 in
50,000 [1]. Depending on the presence or absence of
premature ovarian failure (POF), BPES has been divided
into two subsets: type I is characterized by eyelid malfor-
mation and female infertility through POF, and type II is
characterized by eyelid malformation [2]. Clinically, pa-
tients with BPES experience a combination of congenital
eyelid anomalies characterized by a reduction of the
horizontal fissure length, ptosis, telecanthus and epi-
canthus inversus (that is, below the inner canthus). The
BPES gene was mapped to the 3q23 chromosomal
region [3–7], and mutations in the forkhead box L2
(FOXL2) gene (OMIM# 605597) were subsequently
identified and associated with both types of BPES [8].
Human FOXL2 is a member of the winged helix/fork-
head transcription factor family. Expression studies
have revealed that the FOXL2 protein is present in
the mesenchyme of developing eyelids, in fetal and
adult granulosa cells of the ovary, and in the embry-
onic and adult gonadotropic cells of the anterior pitu-
itary [8–12], suggesting that this protein might play a
key role in regulating the early development of the
eyelids and ovaries and maintaining the female gonads
in vertebrate species [8, 10].
Of all genetic defects identified in BPES, intragenic
mutations represent the largest group (71 %) [13]. Dele-
tions encompassing FOXL2 and located outside its tran-
scription unit represent 12 % and 5 % of molecular
defects respectively [14]. The largest group (44 %) of
unique FOXL2 mutations contains frameshift mutations.
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Following are the in-frame changes (33 %, of which
poly-Ala expansions represent the largest group), the
nonsense mutations (12 %) and finally the missense mu-
tations (11 %) [13]. Several genotype-phenotype correla-
tions emerged after the identification of the FOXL2
mutations. Some authors have found that mutations
resulting in a predicted truncated protein before the poly-
Ala tract are associated with BPES type I, whereas muta-
tions resulting in an extended protein might lead to BPES
type II, but no clear genotype-phenotype correlations have
been confirmed between mutations and BPES types. This
is because the genetic and clinical heterogeneity are found
in and between families with BPES [15, 16].
Here, we report two novel FOXL2 heterozygous muta-
tions identified in Chinese families with BPES. Both a
c.675_690delinsT (p.Ala226_Ala230del) indel mutation
and a c.223C > T (p.Leu75Phe) missense mutation are
associated with BPES type II.
Methods
Patients
The two large Chinese families with BPES were ascer-
tained through the First Affiliated Hospital of Anhui Med-
ical University (Fig. 1). A total of 31 individuals, including
12 affected individuals, were recruited in this study. An
ophthalmologist performed detailed examinations of the
patients, and the following criteria were used to accept a
diagnosis of BPES [17]: blepharophimosis, ptosis, epi-
canthus inversus, and telecanthus. POF was defined as the
cessation of ovarian function under the age of 40 years
and characterized by amenorrhoea, hypoestrogenism and
elevated serum gonadotrophin concentrations. Besides, in
order to distinguish the type of BPES, the clinical data of
female patients were particularly concerned about
(Table 1). The proband of family A (III:7), a boy, was
10 years old and got the pathogenic gene from his father.
The girl proband of family B (IV:2) was diagnosed as BPES
when she was 8. At the time of her birth, her mother was
a 28-year-old BPES patient. Both of the young probands
showed typical features of BPES, including small palpebral
fissure, ptosis of the eyelids, epicanthus inversus, and
telecanthus.
Informed consent was obtained from all participants
or their guardians for research according to the tenets of
the Declaration of Helsinki and Guidance of Sample
Collection of Human Genetic Diseases through the Min-
istry of Public Health of China.
Mutational analysis
Blood samples were collected from all the individuals of
both Chinese families, and genomic DNA was extracted
from the leukocytes of peripheral venous blood using
the phenol-chloroform method. For mutation analysis,
the PCR amplification of the genomic fragments encom-
passing FOXL2 coding regions was performed using four
overlapping sets of primers [8].
PCR was performed with 100 ng genomic DNA,
25 μl 2 × GC-rich buffer, 8 μl of a dNTP mixture
(2.5 mmol/L), 1 U LA Taq (Takara Biotechnology
(Dalian) Co., Ltd), 2 μl (10 μmol/L) of each primer,
and ddH2o to a final volume of 50 μl. The PCR amp-
lification was performed initially at 94 °C for 5 min,
followed by 35 cycles at 94 °C for 60 s, at 60 °C or
63 °C for 50 s, and 72 °C for 60 s, with a final elong-
ation step at 72 °C for 10 min.
Analysis using agarose gel electrophoresis revealed two
fragments in the PCR products amplified by primer 4 in
the Family A patients, while those of unaffected individ-
uals contained a single fragment (Fig. 2). Because these
PCR products could not be adequately sequenced
Fig. 1 Pedigrees of two Chinese families
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directly, the PCR fragments were purified and cloned
into the PMD18-T vector (Takara Biotechnology (Dalian)
Co., Ltd). The constructs were subsequently transformed
into competent DH5α Escherichia coli. The plasmids
were extracted from the positive clones. The cloned frag-
ments of two types were identified by 6 % agarose gel elec-
trophoresis after PCR using the primers mentioned above.
The plasmids were subsequently sequenced on an ABI-
3730 DNA Analyzer (Takara Biotechnology (Dalian) Co.,
Ltd) using BcaBEST sequencing primers RV-M: 5’-
GAGCGGATAACAATTTCACACAGG-3’ and M13-47:
5’-CGCCAGGGTTTTCCCAGTCACGAC-3’.
All other PCR products were analyzed through direct
sequencing using the same sequencing primers as in the
PCR amplification. The sequencing results were analyzed
by the Seqman sequence assembly program within DNAs-
tar software.
Mutation analysis of the entire FOXL2 gene was per-
formed in all living affected members of two families.
Both variations detected in FOXL2 gene were further
evaluated in the family unaffected members as well as in
100 normal controls.
Results
All patients in two families demonstrated the typical fea-
tures of BPES, including small palpebral fissures, ptosis,
telecanthus and epicanthus inversus. None of the pa-
tients exhibited microcephaly, intellectual disability or
other malformations (Fig. 3), and all adult female pa-
tients had offspring (Fig. 1). From the clinical date
(Table 1), female patients have no signs of POF, although
hormone levels data are not available.
The PCR products obtained from all the patients of
family A included two fragments (304 and 289 bp) on
agarose gel electrophoresis. The sequence of the cloned
PCR products obtained from these patients revealed a
novel heterozygous indel mutation, c.675_690delinsT, a
16-bp deletion and a 1-bp (T) insertion (Fig. 4). This
mutation results in a p.Ala226_Ala230del, a deletion of 5
alanine residues of poly-Ala tract in the protein.
A novel heterozygous missense mutation (c.223C > T,
p.Leu75Phe) was detected in the family B (Fig. 4), which
is in the forkhead domain of the FOXL2. This change
was assessed to be deleterious (PROVEAN score =
−3.185) by analysis with the PROVEAN online tool
(http://provean.jcvi.org/index.php), to be not tolerated
by SIFT (http://sift.bii.a-star.edu.sg/index.html), to be
probably damaging by PolyPhen-2 with a score of 0.999
(http://genetics.bwh.harvard.edu/pph2/index.shtml), and
to be disease causing by mutation taster (http://
www.mutationtaster.org/) (Table 2).
Fig. 2 The PCR products amplified by primer 4 in the Family a.
Patients’ PCR products revealed two fragments of 304 and 289 bp
using 6 % agarose gel electrophoresis. Normal individual contained
a single fragment of 304 bp. The right lane is DNA marker (100bp)
Fig. 3 Pictures representing the ocular defects of BPES patients from two Chinese families. Patients experience a combination of congenital
eyelid anomalies: small palpebral fissures, ptosis, telecanthus, and epicanthus inversus. The left is Family (a) and the right is Family (b)
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Fig. 4 Sequencing results of the two novel mutations in FOXL2 (the heterozygous mutation c.675_690delinsT in family a and the missense
mutation (c.223C > T) in family b). The mutant alleles identified in the present study are compared with the normal alleles. The red marks indicate
the position of mutations
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Testing of each mutation showed presence in all af-
fected family members respectively in a heterozygous
state, and absence in the unaffected members and 100
normal controls.
Discussion
FOXL2 is a forkhead transcription factor, containing a
forkhead domain for DNA binding and a poly-Ala tract
[8, 18]. It is encoded by a 2.7-kb DNA sequence with
only one exon that is translated into a protein of 376
amino acids. FOXL2 is highly expressed in developing
eyelids [10, 19], and in the fetal and adult granulosa cells
of the ovary [9–12]. Mutations in FOXL2 are responsible
for BPES both type I and type II [8]. To date, more than
200 mutations in FOXL2 have been associated with
BPES in different populations [14, 17]. Previous studies
have shown the existence of two mutational hotspots:
30 % of FOXL2 mutations lead to poly-Ala expansions,
and 13 % are a novel out-of-frame duplication [15].
In our study, none of the female patients with amenor-
rhoea were mentioned before the age of 40 in clinical
inquiry. The I: 2 female patient of family A was 63 years
old. Her menopause was at 52 years old which was
much older than fourty. Moreover, when she was thirty,
she gave birth to a daughter (II: 6). 34-year-old II: 6 was
also a BPES patient with regular menstrual cycle, and
was two boys’ mother. The female fertility situation of
family B was the same as family A. The affected adult fe-
males in family B did not have fertility problems, but
with regular menstrual cycle. All patients in these two
families exhibited the typical eyelid malformation of
BPES, small palpebral fissures, ptosis, telecanthus and
epicanthus inversus, but without female infertility (POF),
suggesting that the phenotypes of the patients in two
families were BPES type II.
Affected individuals in family A showed an indel mu-
tation c.675_690delinsT, consisting of a 16-bp deletion
and 1-bp (T) insertion, which is predicted to remove 5
out of 14 alanine residues (p.Ala226_Ala230del) from the
poly-Ala tract located downstream of the winged helix/
forkhead domain of the FOXL2 protein. The number of
alanine residues is strictly conserved among the human,
mouse, rat, and goat, suggesting the existence of strong
functional or structural constraints [9]. The exact role of
the poly-Ala tract in FOXL2 is unknown, but the mech-
anism for the molecular pathogenesis of the poly-Ala
expansions in BPES has been suggested to be a result of
cytoplasmic aggregation of the FOXL2 protein as well as
inclusion in nuclear aggregates [16, 20–22], most often
leading to BPES type II [15, 23]. However, this correl-
ation is subject to both intra and inter familial pheno-
typic variations [8, 15, 16, 23, 24]. In this study, the
mutation c.675_690delinsT causes removal of 5 out of
14 alanine residues (Ala-5), leading to a truncation at
the poly-Ala tract, showing that either contraction or
expansion of the poly-Ala tract can result in BPES
type II. This is probably because strong structural or
physico-chemical constraints are imposed to the
length of the polyAla tract: expansion induces cyto-
plasmic retention as well as cytoplasmic and nuclear
aggregation. Contraction would also be deleterious in
the context as the protein might adopt an incorrect
conformation leading to intranuclear aggregation [22].
It is the first report that a partial deletion of the
poly-Ala tract in FOXL2 is associated with BPES type
II, but the other poly-Ala tract partial deletion
(p.Ala221_Ala230del) has been described in one POF
patient with no eye defects [25]. Our data further
support that there are no clear genotype-phenotype
correlations between mutations and BPES types be-
cause the genetic and clinical heterogeneity are found
in and between families with BPES.
Family B showed the c.223C > T (p.Leu75Phe) mis-
sense mutation, which lies within the forkhead domain,
seems likely to interfere with DNA binding, although it
doesn’t lie within a specifically identified DNA binding
site. Most missense mutations identified in FOXL2 occur
within the forkhead domain [15]. Missense changes have
been suggested to act as null allele leading to BPES
phenotype due to haploinsufficiency [16] or dominant-
negative effect [26]. Previous studies indicated that mis-
sense mutations inside or outside the forkhead domain
could determine the expressivity of BPES. Mutations in-
side the forkhead domain might produce a more severe
phenotype, while mutations outside it might produce a
mild phenotype [27]. In our study, the BPES family car-
rying the p.Leu75Phe mutation has a typical clinical
BPES phenotype, which further supports the possibility
that the affected BPES individuals with missense muta-
tion inside the forkhead domain might have a severe
phenotype. The results obtained from pathogenicity pre-
diction software suggest that this mutation may affect
protein function. Taken together, these data testify that
the functional alteration of FOXL2 transcription factor
by the c. 223C > T substitution may be associated with
this severe phenotype BPES.
Conclusions
In conclusion, we found two novel mutations in the
FOXL2 gene in two large Chinese families with
Table 2 FOXL2 mutation (c.223C > T) results from pathogenicity
prediction software
PROVEAN SIFT PolyPhen-2 Mutation
Taster
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individuals affected with BPES type II. An indel muta-
tion c.675_690delinsT (p.Ala226_Ala230del) occurs at the
poly-Ala tract, predicted to remove 5 out of 14 alanine
residues from the poly-Ala tract, leading to contraction
of a highly conserved poly-Ala tract. It is the first report
that a partial deletion of the poly-Ala tract in FOXL2 is
associated with BPES type II. The second is a novel mis-
sense mutation c.223C > T (p.Leu75Phe) occurring within
the forkhead domain, and probably interfering with DNA
binding. These results expand our current understanding
of the spectrum of FOXL2 mutations, especially with
regard to the poly-Ala tract.
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